Top 10 Heal Care Stocks To Own For 2018


Apple (NASDAQ:AAPL) is very rarely a first mover, and CEO Tim Cook often points out that the company’s goal is never to be the first at something — it just wants to be the best. The iPod wasn’t the first music player, the iPhone wasn’t the first smartphone, and the iPad wasn’t the first tablet. There are more examples.

With Facebook (NASDAQ:FB) making a big official push into augmented reality (AR) yesterday, complementing its virtual reality (VR) efforts, will the same scenario play out once again for the Mac maker?


Mark Zuckerberg at F8 2017 unveiling Facebook’s AR platform. Image source: Facebook.

Hardware is hard

Cook has made no secret of how much potential he sees in AR, believing that the nascent technology could be truly transformative since unlike VR, AR doesn’t isolate you from the real world. In characteristic fashion, don’t expect Apple to unveil whatever it’s up to until the company feels like it’s ready for mainstream adoption. In contrast, Facebook is taking the more traditional Silicon Valley approach of incremental iteration.

Top 10 Heal Care Stocks To Own For 2018: Frontier Communications Corporation(FTR)


Advisors’ Opinion:

  • [By Paul Ausick]

    Frontier Communications Corp. (NASDAQ: FTR) dropped about 4.2% on Wednesday to record a new 52-week low of $2.51 against a high of $5.75. The stock closed at $2.62 on Tuesday. Volume was about a third higher than the daily average of around 25 million shares. The company had no specific news Wednesday, but the struggling company continues getting slaughtered.

  • [By Paul Ausick]

    Frontier Communications Corp. (NASDAQ: FTR) dropped 4.8% Thursday, to post a new 52-week low of $2.78 after closing at $2.92 on Wednesday. The stock’s 52-week high is $5.85. Volume was nearly double the daily average of around 23 million shares. The company missed estimates badly on Monday, and its dividend yield has climbed to 14.33%. Look out below if that is cut.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Tuesday was Frontier Communications Corp. (NASDAQ: FTR) which jumped about 4.7% to $1.35. The stocks 52-week range is $1.19 to $5.31. Volume was 46.4 million compared with the daily average 51.0 million shares.

  • [By Paul Ausick]

    Frontier Communications Corp. (NASDAQ: FTR) dropped 0.1% Wednesday, to post a new 52-week low of $2.90 after closing at $2.93 on Tuesday. The stock’s 52-week high is $5.85. Volume was about 25% higher than the daily average of around 23 million shares. The company missed estimates badly on Monday, but has managed somehow to hang onto its 12.77% dividend yield..

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Tuesday was Frontier Communications Corp. (NASDAQ: FTR) which traded down 5.1% at $2.62. The stocks 52-week range is $2.57 to $5.77. Volume was about 175% above the daily average of around 25 million shares. The telecom company had no specific news but was continuing its fall after its fourth quarter earnings.

Top 10 Heal Care Stocks To Own For 2018: Impax Laboratories, Inc.(IPXL)


Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Impax Laboratories Inc (NASDAQ: IPXL) were down around 29 percent to $10.12. Impax Labs reported Q4 adjusted earnings of $0.16 per share on revenue of $198.4 million.

  • [By Keith Speights]

    Impax Laboratories (NASDAQ: IPXL  ) could be watching more closely than Sanofi. The two companies reached a deal last year that allows Impax to begin marketing a generic version of Renvela in 2014. If approved, Zerenex could take away some of the profits that Impax expected to gain.

Top 10 Heal Care Stocks To Own For 2018: International Speedway Corporation(ISCA)


Advisors’ Opinion:

  • [By Monica Gerson]

    International Speedway Corp (NASDAQ: ISCA) is projected to report its quarterly earnings at $0.41 per share on revenue of $146.09 million. International Speedway shares declined 1.65 percent to close at $36.26 yesterday.

  • [By Monica Gerson]

    International Speedway Corp (NASDAQ: ISCA) is estimated to report its quarterly earnings at $0.41 per share on revenue of $146.09 million.


    Mitcham Industries, Inc. (NASDAQ: MIND) is projected to post a quarterly loss at $0.36 per share on revenue of $10.99 million.

Top 10 Heal Care Stocks To Own For 2018: ADDvantage Technologies Group, Inc.(AEY)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggestedshorting small cap cable television and telecommunications equipment stock ADDvantage Technologies Group, Inc (NASDAQ: AEY):

Top 10 Heal Care Stocks To Own For 2018: Barnes Group, Inc.(B)


Advisors’ Opinion:

  • [By Dave and Donald Moenning]

    For those investors that like the comfort generally provided by a diversified portfolio, here’s an idea that will allow you to (a) maintain a diversified allocation in your portfolio and (b) stay out of trouble when the big, bad bears come to call on an asset class or two.

Top 10 Heal Care Stocks To Own For 2018: BofI Holding Inc.(BOFI)

Advisors’ Opinion:

  • [By Matthew Frankel]

    Internet-based bank holding company BofI Holding (NASDAQ:BOFI) is not like most other banks. Since the name BofI stands for “Bank of Internet,” one thing that obviously makes the bank unique is its online-only business model. However, there are a lot of less-obvious things about BofI Holding that you might find interesting.

  • [By Matthew Frankel]

    3. BofI Holding (NASDAQ:BOFI) is a more speculative choice, but one that deserves serious consideration. The bank, whose name stands for “Bank of Internet”, is the oldest internet-only bank in the U.S. By maintaining an online-based business model, the bank enjoys competitive advantage such as low overhead and the ability to offer better rates on loan and deposit products than peers.

  • [By Jason Hall]

    Internet bank holding companyBofI Holding, Inc.(NASDAQ:BOFI) reported financial and operating results on April 25 after market close, with net income of $41 million — the most-ever in a single quarter in its history. BofI delivered strong growth in net interest income, book value, loan originations, and a number of other key metrics.

Top 10 Heal Care Stocks To Own For 2018: Tidewater Inc.(TDW)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, energy shares slipped by 0.20 percent. Meanwhile, top losers in the sector included Northern Oil & Gas, Inc. (NYSE: NOG), down 9 percent, and Tidewater Inc. (NYSE: TDW), down 8 percent.

Top 10 Heal Care Stocks To Own For 2018: ANSYS, Inc.(ANSS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Wednesday's regular session.

Top 10 Heal Care Stocks To Own For 2018: Nomura Holdings Inc ADR(NMR)


Advisors’ Opinion:

  • [By Maureen Farrell]

    Shortly after Lehman declared bankruptcy, Barclays (BCS) paid $1.3 billion for most of the firm’s North American operations, its Times Square headquarters, and about 9,000 employees. Nomura Holdings (NMR) paid roughly $200 million for Lehman’s operations in Asia.

Top 10 Heal Care Stocks To Own For 2018: AbbVie Inc.(ABBV)

Advisors’ Opinion:

  • [By Kumar Abhishek]

    The lower number of patient starts and rising competition has been a major worry for Gilead Sciences Inc. Most of the patients with serious Hep-C conditions have already been cured.It is estimated that more than 1 million Hep-C patients have been cured worldwide. And the entry of competitively priced drugs will further dent the growth of this segment. Gilead’s HCV drugs are facing tough competition from Merck (NYSE:MRK), AbbVie (NYSE:ABBV) and Bristol-Myers Squibb (NYSE:BMY). For example, initially, the price difference between Merck’s treatment plan and Gilead’s plan was a whopping $40,000. The rising competition is also impacting the HCV segment’s margins.

  • [By Jim Crumly]

    Just as the body’s normal stem cells renew and sustain organs and tissue, cancer stem cells do the same for tumors. Large cap drugmaker AbbVie (NYSE:ABBV) is taking the lead in developing drugs to go after cancer stem cells, and long-term investors could enjoy the payoff.

  • [By Javier Hasse]

    8:05:11 am: ABBV WYNN Najarian Brothers See Unusual Options Activity In AbbVie And Wynn Resorts. Jon Najarian spoke on CNBC's "Fast Money Halftime Report" about unusually high options activity in AbbVie Inc (NYSE: ABBV). He said that options traders bought aggressively the October 91 calls. He decided to follow the trade and he is planning to hold it…

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Keith Speights]

    Smart investors will be ready to take advantage of a market pullback, whenever it comes and offers discount prices on great stocks. Three drug stocks appear to be excellent choices to buy on a dip: AbbVie (NYSE:ABBV), Allergan (NYSE:AGN), and Celgene (NASDAQ:CELG). Here’s why.